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Abstract.  Platelet membrane glycoprotein IIb-IIIa 
forms a  calcium-dependent heterodimer and constitutes 
the fibrinogen receptor on stimulated platelets.  GPIIb 
is a two-chain protein containing disulfide-linked ~t 
and 13 subunits. GPIIIa is a  single chain protein.  These 
proteins are synthesized in the bone marrow by 
megakaryocytes, but the study of their synthesis has 
been hampered by the difficulty in obtaining enriched 
population of megakaryocytes in large numbers.  To ex- 
amine the biosynthesis and processing of GPWo-IIIa, 
purified human megakaryocytes were isolated from liq- 
uid cultures of cryopreserved lenkocytes stem cell con- 
centrates from patients with chronic myelogenous 
leukemia. Immunoprecipitation of [35S]methionine 
pulse-chase-labeled cell extracts by antibodies specific 
for the tx or 13 subunits of GPIIb indicated that GPIIb 
was derived from a precursor of Mr  130,000 that con- 
tains the tx and 13 subunits. This precursor was con- 
verted to GPIIb with a half-life of 4-5 h.  No precur- 
sor form of GPHIa was detected. The glycosylation of 
GPI~-IIIa was examined in megakaryocytes by meta- 
bolic labeling in the presence of tunicamycin, monen- 
sin, or treatment with endoglycosidase H.  The poly- 
peptide backbones of the GPIIb and the GPIIIa have 
molecular masses of 120 and 90 kD, respectively. 
High-mannose oligosaccharides are added to these poly- 
peptide backbones co-translationally. The GPIIb 
precursor is then processed with conversion of high- 
mannose to complex type carbohydrates yielding the 
mature subunits GPIIb0t (M~ 116,000) and GPI]bl3  (Mr 
25,000).  No posttranslational processing of GPRIa was 
detected. 
p 
LATELET GPIIb-Ula is a calcium-dependent hetero- 
dimer  making up  18%  of the  platelet membrane- 
associated glycoproteins (12). GPHb is composed of 
two disulfide-linked  polypeptide chains: IIbct and IIb13 of ap- 
parent molecular masses, on SDS gel electrophoresis, of 116 
and 25 kD,  respectively (12, 18). GPIIIa is a  single chain 
polypeptide which has an apparent molecular mass of 100 
kD when reduced (12). GPIlb-HIa is implicated in the plate- 
let adhesive reactions. It serves as a receptor for fibrinogen 
(16), fibronectin (19), and von Willebrand factor (25),  these 
interactions being essential for platelet attachment, spread- 
ing, and aggregation. Recently, two observations have sug- 
gested that GPIlb-RIa is a member of a broadly distributed 
family of membrane adhesion receptors which mediate cell 
adhesion and cell-cell interactions, and for which the desig- 
nation "cytoadhesins" has been proposed. Firstly, the pres- 
ence of antigens related to GPIIb-lIIa on the surface of ceils 
other than platelets has been demonstrated. Certain mono- 
clonal  and polyclonal antibodies  which interact with the 
platelet GPl/b-IIIa immunoprecipitate similar species from 
surface-labeled endothelial cells (8) and leukocytes (6). Sec- 
ondly, GPHb-IBa recognizes Arg-Gly-Asp-containing se- 
quences (22), and is thus a member of the widely distributed 
family of Arg-Gly-Asp-binding receptors  (20,  21). Differ- 
ences in receptor specificity and in the molecular mass of the 
constituent subunits of these receptors have been observed 
according to their cellular origin, suggesting that the differ- 
ences amongst these proteins may result from the transcrip- 
tion of distinct genes.  Alternatively, the subunits of these 
receptors  may derive from a  single gene via cell-specific 
posttranscriptional processing mechanisms. The recent c~b- 
servation that a 20-kb genomic fragment (7) appears to con- 
tain sequences encoding proteins immunologically  related to 
GPIlb-IIIa as well as to OKM-1 and LFA-1, two other mem- 
brane adhesion receptors expressed in leukocytes, is in sup- 
port of the latter hypothesis. The analysis of the posttran- 
scriptional events which occur during the biosynthesis and 
processing of  these adhesion receptors should provide a valu- 
able insight into the molecular mechanisms which control 
the  expression of these  receptors  at  the  surface of these 
different cell types. 
GPIIb-IIIa synthesis is detectable from the early stages of 
megakaryocytopoiesis  (31). As the megakaryocyte  represents 
less than 0.5 % of all bone marrow cells and is difficult to pu- 
rify in large quantities, information on the cellular transit of 
GPIIb-IIIa in human megakaryocytes has not as yet been 
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megakaryocytes from liquid culture of cryopreserved leuko- 
cytes  stem cells  concentrates  from patients  with chronic 
myelogenous leukemia (CML)  1 (3).  High numbers of de- 
veloping megakaryocytes from the megakaryoblast to the 
polyploid mature megakaryocyte can be obtained in these 
liquid cultures (4).  These cells have been shown to express 
not  only  platelet  GPIIb-IIIa  but  also  fibrinogen,  von 
Willebrand factor, and GPIb, which are either not expressed 
or only weakly expressed in established erythroblastic cell 
lines.  Thus,  these megakaryocytes constitute an excellent 
tool for studying the specific nuclear and cytoplasmic mech- 
anisms controlling the biosynthesis and processing of plate- 
let factors. In this study, these cells have been used to exam- 
ine the biosynthesis and processing of GPIIb-IIIa. 
Materials and Methods 
Materials 
Carrier-free t~I (17 laCi/mg)  and [35S]methionine  (1,000 mCi/mmol) Am- 
plifier and molecular mass standards were from Amersham International 
(Amersham, England). P2, an anti-GPllb-ma monoclonal antibody (17) 
was  obtained  from  Immunotech  (Marseille,  France).  BSA,  monensin, 
tunicamycin, Staphylococcus  aureus  Cowan I strain (Pansorbin) and lac- 
toperoxidase were from Calbiochem-Behring Corp. (La Jolla, CA). Oligo- 
dT cellulose was obtained from Bethesda Research Laboratories (Bethesda, 
MD) and endoglycosidase H  (endo H)  was from New England Nuclear 
(Boston, MA). The nuclease-treated rabbit reticulocyte lysate system was 
from Promega Biotec (Madison, WI). The immunoblot assay kit used for 
Western blotting was from Bio-Red Laboratories (Richmond, CA). 
Purification of  Human Megakaryocytes 
Megakaryocytes were obtained from liquid cultures of cryopreserved blood 
cell concentrates from patients in the chronic phase of CML as previously 
described (3, 4). Briefly, leukocytes-enriched fractions were obtained from 
CML patients by leukophoresis, and the leukocytes were separated from 
platelets by low-speed  centrifugation at 300 g for 10 min. The leukocyte pel- 
let was washed twice in Hanks' balanced salt solution (HBSS). Low-density 
cells containing the megakaryoeytic progenitor cells were obtained after 
centrifugation on a BSA density gradient and stored at -1960C using a two- 
step freezing technique, as previously described (2). Culturing of thawed 
cells was performed in T 25 flasks (Falcon Labwares, Oxnard, CA) with 
5  x  106 cells per 10 ml RPMI 1640 medium supplemented with 20% hu- 
man plasma.  Incubation was performed at 370C  in a  5%  CO2 fully hu- 
midified atmosphere. 
GPIIb-IIIa-positive ceils were purified by sorting on a  fluorescence- 
activated cell sorter (FACS IV,  Becton Dickinson, Mountain View,  CA) 
equipped with a 5-W argon ion laser (Spectra-Physics Inc., Mountain View, 
CA). Cells were labeled by indirect immunofluorescence  using P2, a mono- 
clonal antibody which reacts with GPIlb-IHa (17). The purity of the sorted 
cell population was evaluated using standard cytological criteria for mega- 
karyocytic  cells (32).  After sorting,  the  cells were cultured  in  human 
plasma-supplemented RPMI medium for 24 h before use. 
Labeling Procedures 
Metabolic labeling of  proteins synthesized  by the cultured human megakary- 
ocytes was routinely performed in 35-mm plastic dishes containing 2  × 
106  cells/ml in methionine-free RPMI  1640 with 20%  dialyzed human 
plasma and 250 ttCi.  [35S]Methionine  was then added and the cells were 
incubated for up to 8 h at 3"/°C in an atmosphere of 95% air/5% CO2. For 
pulse-chase experiments, cells were initially labeled as above for 30 min 
with 250 IxCi/ml [35S]methionine,  and the pulse was terminated by remov- 
ing the [35S]methionine-containing medium. The cells were washed twice 
with HBSS and incubated with the media containing 20% human plasma 
for intervals of up to 48 h. When labeling was performed in the presence 
of tunicamycin or monensin, the cells were preincubated at  37"C  with 
1. Abbreviations  used in this paper: CML, chronic myelogenous leukemia; 
endo H, endoglycosidase H. 
either 5 ~tg/ml tunicamycin for 2 h or with 2 lag/ml monensin for 16 h. The 
drug  concentrations  were  maintained  throughout  the  incubation  with 
[35S]methionine. 
Washing and Surface Iodination of  Platelets 
Platelets were isolated from acid citrate dextrose anti-coagulated fresh hu- 
man blood by differential centrifugation and gel filtration as previously de- 
scribed (16). The platelets were ultimately suspended in Tyrode's buffer con- 
taining 2 % BSA and tested for aggregation and fibrinogen binding using 
previously described assay systems (15). Washed platelets were surface la- 
beled in the presence of carder-free J:5I using the lactoperoxidase method 
(18). 
Antibodies 
A454 is a goat polyclonal antibody raised against a  purified preparation 
of platelet GPIIb-IIla. Two rabbit antibodies were raised against purified 
GPIFott  and GPIIbl3  subunits from human platelets. To  purify the two 
subunits, platelet membrane extracts were applied to a Sepharose affinity 
column to  which CS9,  a  monoclonal antibody  specific  for GPIIb-IIIa 
produced  in  our  laboratory,  had  been  coupled.  A  fraction  containing 
GPIIb-IIIa was ehited with EDTA at pH 8.9 at 37°C and subjected to elec- 
trophoresis on an exponential 5-20% gradient polyacrylamide gel, under 
reduced conditiom. Electrophoretic bands at 116 and 25 kD corresponding 
to GPI~a and GPIlb[3 were excised, and specific antibodies were prepared 
by subcutaneous injection of rabbits with 20-100  lag of purified subunit 
emulsified in complete Freund's adjuvant. The rabbits were given a booster 
injection 2 wk later with the protein in incomplete adjuvant and then bled 
2  wk after the last injection. Monoclonal antibodies, 22C4  and PMI-1, 
which specifically recognize GPIIIa and GPIIbet, respectively, have been 
previously described (9, 26). 
The specificities of A454, PMI-1, and 22C4 wore tested by immunopre- 
cipitation of lactoperoxidase surface-labeled platelet extract and gel electro- 
phoresis. The specificities of the polyclonal antibodies anti-GPIIbct and 
anti-GPllb[$ were analyzed by Western blot. Briefly,  10 lag of proteins from 
a  1% Triton X-100 platelet extract were subjected to electrophoresis on a 
7-12 % linear gradient acrylamide gel with or without reduction with 5 % 
2-mercaptoethanol. Proteins were transferred onto a nitrocellulose filter, the 
strips incubated with the antisera at a 1:100 dilution for 1 h, and the antibod- 
ies detected using an immunoperoxidase method. 
Preparation of Cell Lysates and Immunoprecipitation 
After labeling, the cells were washed twice with ice-cold PBS and lysed 
with lysis buffer (1% Triton X-100 and 2 mM phenylmethylsulfonyl  fluoride 
[PMSF] in PBS, pH 7.4) for 20 min on ice. The lysate was clarified by cen- 
trifngation at 11,000 g for 10 rain. 1 ml of cell extract was treated with 100 
lal of a  10% Staphylococcus  aureus  Cowan I strain suspension for 30 min 
at 4°C. The Pansorbin was removed by centrifugation and 100 ~tl of the cell 
lysate diluted with 4 vol of washing buffer (1% Triton X-100, 0.5% SDS, 
0.5% sodium deoxycholate, 0.5% BSA in PBS, pH 7.4) and incubated for 
16 h at 4°C with 5-20 lal of specific antibodies against GPIIb and GPIIIa. 
The immunoprecipitate was washed twice with I ml washing buffer and then 
eight times with washing buffer without BSA. After the washing steps, the 
adsorbed immune complexes were dissociated by boiling for 5 min at 100°C 
in 50 mM Tris-HCl, pH 6.8, containing 5% mercaptoethanol, 2% SDS, 
10% glycerol, and 0.01% bromophenol blue. The samples were clarified by 
centrifugation at 11,000 g for 5 rain and analyzed by SDS-PAGE on either 
7. 5 % gels or linear gradient gels of 7-12 %, according to Laemmli (14). After 
electrophoresis, the gels were fixed for 30 min with 7 % acetic acid and 
treated with Amplify for 30 min, dried under vacuum at 80°C, and exposed 
to Kodak X-O Mat film at -70°C, using Dupont Cronex Lighting Plus inten- 
sifying screens. 
Treatment of  Proteins with Endo H 
35S-labeled proteins were isolated by immunoprecipitation with antiserum 
A454,  and fractionated by SDS-PAGE as described above. The [35Slme- 
thionine-labeled bands, detected by autoradiography, were excised from the 
gels using the autoradiograph film as a template. Sample buffer containing 
SDS and 5% 2-mercaptoethanol was added to each band, and the gel was 
then crushed. Digestions with endo H were performed in the presence of 
0.1 M sodium citrate buffer (pH 5.5) containing 2 mM PMSF and 7 gg/ml 
of the enzyme. After 18 h of incubation, the reaction was stopped by heating 
for 2 rain at 100°C. 
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Total RNA was  isolated from cells using the  guanidin-hydrochloride 
method (13) in the presence  of  ianrylsarkosine. Poly (A)-rich RNA was iso- 
lated by oligo-dT  cellulose chromatography  of total RNA (1). 4 ~tg of Poly 
(A)  + mRNA were incubated with [35S]methionine (2 mCi/ml) and reticulo- 
cyte  lysate  for 90 min at 30°C in a total volume  of 100 ~tl. After incubation, 
PMSF was added at a final concentration  of 2 mM and incorporation  of ra- 
dioactivity  in the translation assay was determined by removing  l-l,  tl aliquots 
and measuring the radioactivity precipitated by 10% TCA. 
Results 
Specificity of the Antibodies 
The specificity of these antibodies is demonstrated in Fig.  1. 
On immunoprecipitation of lactoperoxidase surface-labeled 
Figure 1.  Specificity  of anti- 
bodies against  platelet  GPIIb 
and  GPIIIa.  (A)  Surface-io- 
dinated  washed platelets  were 
lysed  in  PBS  containing  1% 
Triton X-100 and 2 mM PMSE 
An aliquot of this extract (2 × 
106 cpm) was  incubated  with 
10 Ill of the selected  antibody 
and  100 lal of 10%  Staphylo- 
coccus aureus Cowan  I  (see 
Materials  and Methods).  The 
immunoprecipitate  was  sub- 
jected to electrophoresis on a 
7.5% polyacrylamide gel un- 
der reducing  conditions.  Dis- 
play of t25I was monitored by 
autoradiography  of the dried 
gels. Immunoprecipitation was 
performed  with  A454  (lane 
1), 22C4 (lane 2), and PMI-1 
(lane 3). (B) Western blotting 
of platelet  membrane extract 
with anti-GPIIbct  (lanes 1 and 
2)  and  anti-GPIIbl~  (lanes  3 
and 4).  Lanes 1 and 3 repre- 
sent  the nonreduced samples 
and lanes 2 and 4 represent the 
reduced  proteins.  Molecular 
masses  are  shown  as  Mr  x 
10-3. 
platelet extract and gel electrophoresis under reduced condi- 
tions, A454 precipitated bands at 116 and 100 kD (Fig.  1 A, 
lane 1) and monoclonal antibodies 22C4 and PMI-1 bands 
at 100 and 116 kD, respectively (Fig.  1 A, lanes 2 and 3). By 
Western blotting, the antibody anti-GPIIba recognized elec- 
trophoretic bands at 130 (nonreduced) and 116 (reduced) kD 
(Fig.  1 B, lanes  1  and 2),  while the antibody anti-GPIIbl3 
blotted electrophoretic bands at 130 (nonreduced) and 25 (re- 
duced) kD (Fig.  1 B,  lanes 3  and 4). 
Characterization of Purified Megakaryocytes 
Large numbers of megakaryocytes were obtained in liquid 
cultures of cryopreserved blood cell concentrates from pa- 
tients in the chronic phase of CML (3, 4). The thawed blood 
Figure  2.  (A)  May-Grun- 
wald-Giemsa staining of  CML 
thawed cells cultured for 12 d, 
showing  polyploid  granular 
megakaryocytes amongst my- 
eloid  granulocytic cells.  (B) 
May-Grunwald-Giemsa  stain- 
ing of  the same cell suspension 
after immunolabeling and sort- 
ing,  showing  purified  mega- 
karyocytic cells at all stages of 
maturation.  Bar,  30 Ixm. 
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Megakaryocytes Preparation 
Suspension 
Percentage of total cell in the suspension 
Megakaryocytes Myeloid  cells Macrophages 
Day-10 liquid cultures 
(unseparated)  45  47  8 
After sorting  92  6.5  1.5 
cell concentrates were cultured for 10-12 d in RPMI medium 
supplemented with 20% human plasma. When assessed by 
standard  cytological criteria (32),  these cultures contained 
40-60 % megakaryocytic cells. A representative microscopic 
view of a  cell preparation  is  shown  in  Fig.  2  A.  Further 
purification of the megakaryocytes was obtained by sorting 
the cells on a  FACS-IV after indirect immunofluorescence 
labeling  with  a  monoclonal antibody  (P2)  against GPIIb- 
IIIa. Sorting resulted in cell suspensions containing >90% 
megakaryocytes. A representative microscopic view is shown 
in Fig. 2 B. After purification, the megakaryocytes were cul- 
tured for an additional 24 h in human plasma-supplemented 
RPMI at a cell density of 1  x  106 per ml.  The cytological 
composition of a megakaryocyte preparation before and after 
sorting is illustrated in Table I. The sorted cell suspension 
contained <10%  myeloid and macrophagic cells, the major 
contaminating cells in these CML leukocyte cultures. 
Analysis of GPIIb and GPIIIa Produced 
by Human Megakaryocytes 
A series of experiments were performed to identify and char- 
acterize the GPIIb- and GPIIIa-related proteins produced by 
the purified megakaryocytes. Initially, the cells were meta- 
bolically labeled with [35S]methionine  for 8 h  and the im- 
munoreactive species precipitated from cell lysates with the 
various antisera and analyzed by SDS-PAGE under reducing 
conditions.  The results are summarized in Fig.  3 A. Three 
major  electrophoretic  bands  with  estimated  molecular 
masses of 130, 116, and  100 kD (reduced)  were detected in 
the  immunoprecipitates of the  polyclonal anti-GPIIb-IIIa 
A454  (Fig.  3  A,  lane  1).  Monoclonal  antibody  22C4, 
specific for GPIIIa, immunoprecipitated a protein at 100 kD 
(Fig. 3 A, lane 2), while the monoclonal PMI-1, specific for 
GPIIbct, immunoprecipitated bands at 130 and 116 kD (Fig. 
3 A, lane 3). Controls of nonimmune goat IgG and nonim- 
mune  ascite  were  performed  replacing  the  A454  or  the 
monoclonal  antibodies,  respectively.  No  bands  were  de- 
tected in these controls. Fig. 3 A, lane 4, shows the nonim- 
mune goat IgG control.  Furthermore,  immunocompetitive 
experiments with the polyclonal antibody in the presence of 
a large excess of cold platelet membrane extracts resulted in 
Figure 3. SDS-PAGE of platelet GPIIb and GPUIa produced by human megakaryocytes. After metabolic labeling for 8 h with [35S]methio- 
nine, the cells were solubilized in PBS containing 1% Triton X-100 and 2 mM PMSE The newly synthesized GPIlb- and GPllIa-related 
proteins were immunoprecipitated and analyzed on 7.5 % SDS-polyacrylarnide gels. (A) The samples were immunoprecipitated immediately 
after labeling and reduced before electrophoresis.  Lane 1, Precipitation with A454; lane 2, precipitation with 22C4; lane 3, precipitation 
with PMI-I; lane 4, precipitation with A454 in the presence of 10 ~tg proteins from platelet membrane extract; lane 5, precipitation with 
goat nonimmune serum. (B) Reduced and nonreduced samples were compared. (Lanes I and 2) Immunoprecipitation was performed with 
A454 immediately after labeling and the samples were either reduced (lane 1 ) or nonreduced (lane 2).  (Lanes 3 and 4) The cells were 
cultured in medium containing cold methionine for an additional 72 h after labeling, and the immunoprecipitates were reduced (lane 3) 
or nonreduced (lane 4). (C) Subunit composition of the 130- and 90-kD nonreduced species. The two bands at 130 and 90 kD from B, 
lane 4, were excised from the gel, reduced,  and analyzed separately on a 7-12  % linear gradient polyacrylamide gel. Lane 1 shows the 
analysis of the 130-kD band and lane 2 shows the analysis of the 90-kD band.  The fluorograms were obtained as described  in Material 
and Methods.  Molecular  masses are shown as Mr  x  10  -3. 
The Journal of Cell Biology, Volume 104, 1987  1668 Figure 4.  Time course of biosynthesis of GPIIb and GPIIIa in human megakaryocytes. (A) Purified human megakaryocytes were pulsed 
for 30 min with [35S]methionine and chased as described in Material and Methods. The proteins were immunoprecipitated from cells ex- 
tracts at selected time points with A454. The samples were analyzed on a linear gradient from 7-12  % SDS-polyacrylamide  gels after reduc- 
tion with 5 % 2-mercaptoethanol.  (B) The fluorogram was scanned densitometrically  with a Vernon spectrophotometer  and the relative 
intensities of  the 130-, 116-, and 25-kD proteins were plotted as a function of  the chase time. (C) Megakaryocytes were metabolically labeled 
for 8 h in the presence of [35S]methionine. Immunoprecipitations were performed in the presence of anti-GPIlba (lane 2) or anti-GPIIbl3 
(lane 1) either after reduction and alkylation of the cell lysates and analyzed with a 7-12  % linear gradient polyacrylamide gel (lane 1 and 
2) or before reduction and analysis with a 7.5% polyacrylamide-SDS  gel. Due to the low intensity of the 25-kD band,  the lower part of 
the gel was autoradiographed for 7 d. The upper portion of the fluorogram was obtained after 1 d of exposure. Molecular masses are shown 
as Mr  x  10  -3. 
the  loss  of  detectable  bands  after  SDS-PAGE.  The  im- 
munoprecipitate obtained with A454 has been compared un- 
der reducing and nonreducing conditions in Fig. 3 B. After 
8  h  of metabolic labeling,  A454  precipitated  three  major 
bands at  130, 116, and  100  kD,  under reducing conditions 
(Fig. 3 B, lane 1 ). When the immunoprecipitate was run un- 
der nonreducing conditions,  bands at  130, 120, and 90 kD 
were detected (Fig. 3 B, lane 2). To identify the mature forms 
of GPIIb and GPIIIa produced by the megakaryocytes, the 
cells were labeled with [35S]methionine  for 8 h followed by 
an incubation in normal cold medium for 72 h. Under these 
conditions two electrophoretic bands were immunoprecipi- 
tated by A454 with apparent molecular masses of 116 and 100 
kD (reduced)  and  130 and 90 kD (nonreduced)  (Fig.  3 B, 
lanes 3  and 4). 
The two electrophoretic bands  with apparent molecular 
masses of 130 and 90 kD under nonreducing conditions were 
excised,  reduced  with  5 %  2-mercaptoethanol,  and  reana- 
lyzed separately on a 7-12 % linear polyacrylamide gel. Un- 
der these conditions,  the  130-kD protein resolved into two 
subunits of 116 and 25 kD (Fig. 3 C, lane 1). When the pro- 
tein at 90 kD was reduced it migrated as a  100-kD species 
(Fig. 3 C, lane 2).  Due to (a) similarities in electrophoretic 
properties and estimated molecular masses with those previ- 
ously reported for reduced and nonreduced GPIIb and GP- 
IIIa, (b) the selective immunoprecipitation of electrophoretic 
bands with specific monoclonal antibodies, and (c) neutral- 
ization of the immunoprecipitation by proteins from platelet 
membranes, it was concluded that the band at  100 kD was 
the reduced  form of GPIIIa having an apparent molecular 
mass of 90 kD when nonreduced. The electrophoretic band 
at 116 kD was the reduced form of GPIIba which when non- 
reduced has an apparent molecular mass of 130 kD. The elec- 
trophoretic band at 130 kD (reduced) which was specifically 
recognized  by  the  monoclonal  anti-GPIIb  presumably 
represents a precursor form of the GPIIb. Under nonreduc- 
ing  conditions  this  pro-GPIIb has  an  apparent  molecular 
mass of  120  kD  (Fig.  3  B,  lane  2).  This  hypothesis  was 
confirmed in subsequent pulse-chase experiments. 
Pulse-Chase Kinetic Analysis 
Posttranslational modifications of GPIIb and GPIIIa  were ex- 
amined  in  pulse-chase  experiments.  Megakaryocytic cells 
were pulsed  with  [35S]methionine  for  30  min  and  chased 
with cold culture medium for 0 to 48 h. The immunoreactive 
forms of GPIIb and GPIIIa were precipitated with A454 and 
analyzed on SDS-polyacrylamide gels under reducing con- 
ditions (Fig. 4 A). Immediately after the 30-min pulse (0 h 
of chase), two bands at 130 and 100 kD were obtained. Den- 
sitometric scanning of the autoradiograms indicated that the 
intensity of the 100 kD band did not change significantly over 
the subsequent 48 h, while the band at 130 kD decreased in 
intensity with a half-life of 4-5 h (Fig. 4 B). Simultaneously 
the appearance and intensification of the 116 and 25 kD elec- 
trophoretic bands was observed. These bands were first de- 
tected after 1 to 2 h, while 48 h was required for the complete 
disappearance of the pro-GPIIb. Short-term pulse-chase ex- 
periments (10-min pulse and 30-min chase) were performed 
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ment  of the  130-, 116-, and 
100-kD  forms  of GPIIb and 
GPIIIa. Megakaryocytes  were 
labeled  with  [35S]methionine 
for 8 h and immunoprecipita- 
tion was performed with A454. 
The  samples  were  reduced 
with  5%  2-mercaptoethanol 
and subjected to electrophore- 
sis  on  7%  SDS-polyacryl- 
amide gels (lane 1 ). The elec- 
trophoretic bands at 130-, ll6-, 
and 100-kD were exised, treat- 
ed  separately  with  7  lag/ml 
endo H for 16 h, and reelectro- 
phoresed.  The  lane  2  repre- 
sents the 130-kD band, lane 3 
the  ll6-kD band,  and lane  4 
the  100-kD band  after treat- 
merit with endo H.  (B) Cell-free  translation  of a megakaryocyte  mRNA preparation.  The mRNA were translated  as described and the 
newly synthesized  proteins  were immunopurified  with nonimmune IgG (lane 1 ), A454 (lane 2), PMI-1 (lane 3), and electrophoresed on 
7.5%  SDS-polyacrylamide gels in the presence of 2-mercaptoethanol.  Molecular masses are shown as Mr  ×  l0  -3. 
to detect possible early posttranslational events in the biosyn- 
thesis,  but none were observed. 
The Pro-GPllb Contains GPIIbQ and GPIIbf3 Subunits 
Definitive evidence that the 130-kD band represented a pre- 
cursor form of GPIIb containing both the ¢t and [3 subunits 
of mature GPIlb was obtained by immunoprecipitation with 
antisera  specific  for each  subunit.  As  shown in Fig.  4  C, 
when the cell lysate was first reduced and alkylated, the anti- 
GPIII3 immunoprecipitated the band at 130 kD and a protein 
of 25  kD  corresponding  to  the  GPIIb[~ subunit  (lane  1), 
while the anti-GPIIbct immunoprecipitated the two bands of 
130  and  116 kD.  This  result demonstrates that the  specific 
anti-GPHbl~ immunoprecipitated the pro-GPIlb confirming 
the presence  of GPIIb[3 epitopes on the precursor form of 
GPIIb. 
Endo H Treatment of the Different 
Forms of  GPIIb and GPIIIa 
The nature of the oligosaccharide side chains present on the 
different molecular forms of GPIIb and GPIIIa produced by 
megakaryocytes was then investigated by examining their re- 
sistance to endo H. This enzyme removes unprocessed high- 
mannose oligosaccharide side chains from glycoproteins but 
does not cleave fully processed oligosaccharide side chains 
(28). The 130-,  116-, and 100-kD bands obtained by immuno- 
precipitation with A454 from [3SS]methionine-labeled cells 
were excised and treated with 7  0g/ml endo H  for 16 h  and 
reelectrophoresed  on 7.5%  SDS-polyacrylamide gels.  The 
fluorograms depicted in Fig. 5 A show that the mobilities of 
the 130- and 100-kD bands were altered while the protein of 
116 kD was resistant to endo H. Deglycosylation of the pro- 
GPIIb form changed its estimated molecular mass from 130 
Figure 6. (A) Effect of tunicamycin on the bio- 
synthesis of GPIIb and GPIIIa by megakaryo- 
cytes.  The  ceils  were  incubated  at  1  x  106 
ceUs/ml in the presence of 5 Ixg/ml  tunicamycin 
for 2  h  before  labeling  with  [35S]methionine 
for an additional 8 h. Immunoprecipitation was 
performed with A454. The fluorogram shows 
the production of the polypeptides in the ab- 
sence (lane  1) or in the presence (lane  2) of 
tunicamycin.  (B) Effect of 2 gM monensin on 
the production of GPIIb by megakaryocytes. 
GPIIb and  GPIIIa were  immunopreeipitated 
from the cell lysate with A454 (lanes I and 2), 
22C4 (lane  3),  and  PMI-I  (lane  4).  Lane 1 
represents  a control labeling experiment in the 
absence of monensin.  Molecular masses  are 
shown as Mr  ×  10  -3. 
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a cell-free translation system programmed with megakaryo- 
cytic mRNA  using  both  A454  and  the  monoclonal anti- 
GPIIb~t,  PMI-1 (Fig. 5 B, lanes 2 and 3). A minor band of 
low molecular mass can be seen, possibly representing in- 
completely translated peptides. Thus the 120-kD protein, de- 
rived from the 130-kD  species by endo H treatment, prob- 
ably represents fully deglycosylated pro-GPllb. The GPIIIa 
species, produced by the megakaryocytes, was also sensitive 
to endo H. Treatment by this enzyme reduced its apparent 
molecular mass from 100 to 90 kD under reducing condi- 
tions. 
Effect of  Glycosylation on the Processing 
of  GPIIb and GPIIIa 
Tunicamycin, an antibiotic which blocks co-translational ad- 
dition of N-linked oligosaccharide to the growing polypep- 
tide (30)  affected GPIlb and  GPIIIa processing.  Fig.  6  A 
shows that tunicamycin inhibited the formation of the 130-, 
116-, and  100-kD  bands and two major proteins of 120 and 
90 kD were immunoprecipitated. In the presence of tunica- 
mycin, some minor bands were observed and represent non- 
specific immunoprecipitated proteins. 
Monensin which blocks the processing of N-linked oligo- 
saccharides from high-mannose to the complex type in the 
Golgi cisternae (27, 29),  also affected GPIIb biosynthesis 
(Fig.  6  B).  Immunoprecipitation experiments with  A454 
showed that the mature GPI/b was not produced in the pres- 
ence of monensin (Fig. 6 B, lane 2). PMI-1 immunoprecipi- 
rated the pro-GPIIb at  130 kD (Fig. 6 B, lane 3) and 22C4 
the GPIIIa at 100 kD (Fig. 6 B, lane 4). These data support 
the hypothesis that glycosylation and carbohydrate process- 
ing  is  a  prerequisite  for the  conversion of pro-GPIIb  to 
GPIIb. 
Mature GPIIb Form is Expressed on the Cell Surface 
While the Pro-GPIlb is an Intracellular Form 
To assess whether both the pro-GPIIb and GPIIb were ex- 
pressed at the surface of megakaryocytes, the cells were sub- 
jected to lactoperoxidase-catalyzed  surface labeling followed 
by immunoprecipitation with A454.  The results are shown 
in Fig. 7.  This antibody immunoprecipitated reduced elec- 
trophoretic bands corresponding to the mature form of  GPIIb 
and  GPIIIa from surface-labeled megakaryocytes (Fig.  7, 
lane 2). The presence of the pro-GPIIb form was simultane- 
ously detected in metabolically labeled megakaryocytes (Fig. 
7, lane 1). Control experiments with surface-labeled plate- 
lets  indicated  that  the  GPI/b  and  GPIIIa of platelets  and 
megakaryocytes were of similar molecular masses  (Fig.  7, 
lane 3). These results suggest that only the mature GPIIb and 
GPIIIa forms are accessible at the cell surface. 
Discussion 
The present study indicates that human megakaryocytes pro- 
duce platelet GPUb-IIIa.  Previous studies using either en- 
riched bone marrow megakaryocytes (23) or megakaryocytes 
from human committed megakaryocytes progenitor cells (11) 
have demonstrated the synthesis of  GPIIb and GPIIIa in these 
cells.  The  source of megakaryocytes used  in  the  present 
study was cryopreserved  blood ofCML paticats. These sam- 
pies offer the distinct advantage in that large numbers of de- 
Figure 7. Immunoprecipitation of surface labeled GPIIb and GP- 
IIIa.  Purified megakaryocytes were labeled with [35S]methionine 
for 8 h (lane 1 ) or surface labeled with 1251 using the lactoperoxi- 
dase method (lane 2). Immunoprecipitations were done with the an- 
tiserum A454. Lane 3 represents immunoprecipitation of GPIIb 
and GPIIIa obtained with the same antiserum from surface iodi- 
nated platelets. A fluorograph of a 7.5 % polyacrylamide-SDS gel 
performed under reducing conditions is shown. Molecular masses 
are shown as Mr  x  10  -3. 
veloping megakaryocytes (20-100  ×  1~)  can be obtained 
for the study of the biosynthesis of platelet factors. Further- 
more, these cells can be purified by fluorescence-activated 
cell (FAC) sorting to >90%  homogeneity and exhibit a ca- 
pacity to differentiate (4).  The present study has  demon- 
strated that human megakaryocytes synthesize the glycopro- 
teins IIb and l~a separately. No precursor form, common to 
both the GPIab and the GPIIIa, could be detected even during 
short time pulse-chase experiments. In contrast the a  and 13 
subunits of GPIlb were derived from the same precursor. 
Bray et al. have reported cell-free translation studies in the 
erythroblastic cell line, HEL, and obtained a similar biosyn- 
thetic system for the GPITo-IZIa (5).  Thus, the GPIIb and 
GPIIIa are the end products of separate genes while a single 
gene codes for the ¢t and 13 subunits of GPIIb. 
GPIIIa is synthesized as a single chain glycoprotein having 
an apparent molecular mass of 100 kD (reduced) or 90 kD 
(nonreduced). These values are similar to previously pub- 
lished  molecular  masses  of the  reduced  and  nonreduced 
forms of platelet GPIIIa. The protein did not exhibit detect- 
able changes in its estimated molecular mass during pulse- 
chase experiments over a 48-h period, suggesting that the oli- 
gosaccharide side  chains  added  co-translationally are  not 
further processed. In contrast, mature GPIIb derives from 
a posttranslational processing of a single polypeptide chain, 
the pro-GPIIb moiety, with an apparent molecular mass of 
130 (reduced) or  120 (nonreduced) kD.  This difference in 
molecular  mass  suggests  that  intrachain  disulfide  bonds 
influence the conformation of the nonreduced form of pro- 
GPIIb. 
The precursor-product relationship between pro-GPIIb 
and GPIIb was established from the following observations: 
(a) immunoprecipitation of pro-GPIIb with PMI-1, a mono- 
clonal antibody specific for the GPIIbct; (b) pulse-chase ex- 
periments showing the gradual disappearance of the precur- 
sor and the simultaneous production of the 0t and 13 subunits 
of GPIIb; (c) the acquisition of endo H resistance with time; 
and (d) the capacity of the precursor to interact with specific 
antibodies directed against  GPIIbct and GPIIb13. This last 
observation confirmed that the reduced form of pro-GPIIb 
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pro-GPIIb  and  mature  GPIIb  involves  a  posttranslational 
proteolytic event. The pulse-chase experiments indicate that 
the production of mature GPIIb is a slow process, 48 h being 
necessary  for the total disappearance of the precursor. 
GPIIb-IIIa is a glycoprotein and glycosylation influences 
its biosynthesis and expression at the cell surface. Tunicamy- 
cin, which inhibits N-glycosylation but not O-glycosylation, 
induces the formation of the aglycoforms of pro-GPIIb and 
GPIIIa, but mature GPIIb was not produced when its precur- 
sor was  not glycosylated.  The  120-kD  form of pro-GPIIb 
synthesized in the presence of tunicamycin is most probably 
the nonglycosylated pro-GPIIb, as a similar nonglycosylated 
120-kD pro-GPIIb can be identified in a cell-free translation 
mixture  of megakaryocyte  mRNA.  Furthermore,  the pro- 
GPIIb is sensitive to endo H and treatment with this enzyme 
yields a single polypeptidic chain of 120 kD.  Similar results 
were  obtained for GPIIIa.  Both tunicamycin and endo  H 
treatments generated a single electrophoretic band of 90 kD. 
This value is in agreement with that previously reported for 
the nonglycosylated form of GPIIIa  synthesized by mRNA 
from the HEL cell line (5) and may well represent the fully 
deglycosylated form of GPIIIa.  We were unable to immuno- 
precipitate the aglyco-form of GPIIIa in cell-free translation 
experiment with A454. A454 was raised against nonreduced 
GPIIb-IIIa  and, as pointed out by Bray et al. (5), the transla- 
tion product of the GPIIIa mRNA is not recognized by this 
type of antibody. Thus, it can be concluded that pro-GPIIb 
and GPIIIa  contain N-linked oligosaccharides of the high- 
mannose type. In contrast, mature GPIIb was endo H resis- 
tant,  suggesting that the processing  of the oligosaccharide 
side chains of this glycoprotein occurs in the Golgi cisternae. 
This is supported by the results of experiments in the pres- 
ence of monensin. Monensin interferes with the intracellular 
transport and processing of glycoproteins. It has no effect on 
the production of glycosylated pro-GPIIb and GPIIIa, again 
suggesting that GPIIIa  carbohydrates moieties are not pro- 
cessed.  In  contrast,  the production of mature  GPIIb  was 
stopped, indicating that either monensin interferes with the 
proteolytic cleavage which transforms the pro-GPIIb into the 
two chain GPIIb, or that the processing of the N-linked high- 
mannose side chains is a prerequisite in the precursor-prod- 
uct transition. The proteolytic cleavage occurred either be- 
fore or after the passage through the Golgi system. This type 
of processing is not unique to the GPIIb and has also been 
described for the other proteins (10, 24). The pulse-chase ki- 
netic analysis suggests that 1-3 h are necessary for process- 
ing the high-mannose oligosaccharide  side chains of pro- 
GPIIb. 
The present study gives some insight into the details of the 
biosynthesis of GPIIb and GPIIIa in human megakaryocytes. 
GPIIb-IIIa resembles the majority of the membrane glyco- 
proteins in their pattern of N-linked oligosaccharide biosyn- 
thesis.  Differences  in the glycosylation of the two subunits 
have been identified. The glycosylation of GPIIIa occurs co- 
translationally and the glycoprotein then undergoes no fur- 
ther processing. In contrast, the production of mature GPIIb 
is dependent upon the processing of the carbohydrate moiety 
and  this  is  probably  the  rate-limiting  step  in  GPIIb-IIIa 
production. The present study does not however determine 
whether GPIIIa associates with pro-GPIIb or solely with the 
mature  form  of GPIIb.  These  possibilities  are  now under 
investigation.  The  results  obtained  using  surface-labeled 
megakaryocytes indicate that only the mature form of GPIIb 
is expressed at the cell surface. Experiments to demonstrate 
binding of fibrinogen to megakaryocyte were unsuccessful 
(our unpublished results). Thus the acquisition of the fibrin- 
ogen receptor activity may well occur postsynthetically dur- 
ing platelet formation. 
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